Financial Contrast: Glucose Health (OTCMKTS:GLUC) vs. Abbott Laboratories (NYSE:ABT)

Glucose Health (OTCMKTS:GLUC) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Risk & Volatility

Glucose Health has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.

Earnings & Valuation

This table compares Glucose Health and Abbott Laboratories”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glucose Health	$380,000.00	12.53	-$320,000.00	($0.03)	-7.76
Abbott Laboratories	$44.33 billion	4.35	$6.52 billion	$3.72	29.80

Abbott Laboratories has higher revenue and earnings than Glucose Health. Glucose Health is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Glucose Health and Abbott Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	-108.70%	N/A	N/A
Abbott Laboratories	14.72%	17.94%	10.86%

Institutional and Insider Ownership

75.2% of Abbott Laboratories shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Glucose Health and Abbott Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	0.00
Abbott Laboratories	0	4	16	2	2.91

Abbott Laboratories has a consensus target price of $137.05, suggesting a potential upside of 23.62%. Given Abbott Laboratories’ stronger consensus rating and higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Glucose Health.

Summary

Abbott Laboratories beats Glucose Health on 13 of the 15 factors compared between the two stocks.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.